REGN — Regeneron Pharmaceuticals, Inc.

The market is constructive after Q2 2026 revenue grew 16.7% YoY to $4.29B, Dupixent global sales rose 38% to a record $6.0B, and Eylea HD U.S. sales overtook the older Eylea formulation. The full repayment of the Sanofi development balance also removes a long-standing economics overhang. Analysts are Buy-rated (34 buy, 15 hold, 0 sell), though the active securities class action and weak Q2 free cash flow have kept sentiment from becoming euphoric.

Revenue has clearly inflected higher in 2026: after roughly flat growth in 2024-2025, Q1 2026 and Q2 2026 grew 19.0% and 16.7% YoY to $3.61B and $4.29B. Operating margin expanded to 33.1% in Q2 2026 versus 29.4% a year earlier, although 2025 margins had compressed (Q4 2025 was 22.7%). Net income still fell 6.8% YoY in Q2 2026 because R&D jumped to $1.63B from $1.43B. TTM free cash flow is roughly $3.52B, but Q2 2026 FCF dropped to $334M from $968M a year ago—a cash-flow timing flag worth watching. This is an acceleration story, not a structural decline.

As of 2026-08-27, trailing P/E is 19.3x versus the 5-year average of 17.0x, but forward P/E on the next-fiscal-year EPS estimate of $54.24 is about 14.9x, below its historical average. Price-to-sales of 5.36x is also below the 5-year average of 5.74x. The trailing PEG of 61.9 is misleading because trailing EPS growth was depressed; on forward estimates the stock looks reasonably priced. Overall valuation is fair—not a bargain, not excessive.

At $807.71, the market is paying roughly 14.9x forward earnings, which prices in continued Dupixent and Eylea HD momentum but does not price in major pipeline upside. If Q3 2026 confirms the margin lift from the Sanofi balance repayment, a re-rating toward the high-$800s is plausible. But if Q2's weak operating cash flow recurs or the litigation picture worsens, the 14.9x forward multiple offers limited valuation cushion.

As of 2026-08-27, RSI stood at 61.64, price was $807.71, and REGN was +0.82% above its 20-day, +13.3% above its 50-day, and +10.95% above its 200-day moving average. The stock is trending upward but not overbought, sitting near the upper end of its 541-847 52-week range. Immediate support is around the 20-day near $801, with stronger support near the 50-day around $713; resistance is the 52-week high near $847. Chasing here is not ideal—a pullback toward the 50-day would improve the entry.

• Low beta of 0.24 and a clean balance sheet make REGN a defensive-growth large-cap biotech in an uncertain interest-rate environment.
• Drug pricing scrutiny and Medicare negotiation remain sector overhangs, though Dupixent and Eylea have entrenched adoption and patent protection into the next decade.
• Ophthalmology biosimilar competition is the key competitive sector factor; Eylea HD mix shift is the company's main counter.
• Capital allocation has improved with a new dividend, buybacks, low leverage, and the full repayment of the Sanofi development balance.
• Sector rotation: REGN has lagged higher-beta biotech ETFs like XBI in 2026, leaving potential catch-up if risk appetite stays firm.

• Q3 2026 earnings in late October/early November—the first full quarter without the Sanofi development balance deduction, which should lift reported economics.
• September 2026 investor conferences: Wells Fargo Healthcare Conference on Sept 9, Morgan Stanley Global Healthcare Conference on Sept 14, and Bernstein Healthcare Forum on Sept 23.
• Regulatory updates for cemdisiran in generalized myasthenia gravis and garetosmab for FOP could add pipeline visibility.
• Continued Eylea HD U.S. share gains and Dupixent label-expansion momentum.

• Securities class action with a lead-plaintiff deadline of September 14, 2026, tied to the May 2026 Libtayo combination trial PFS miss.
• Eylea biosimilar erosion could pressure the ophthalmology franchise if Eylea HD share gains do not fully offset.
• Cash-flow volatility: Q2 2026 OCF fell to $574.5M and FCF to $334.3M versus $967.6M FCF in Q2 2025; if recurring, it would lower earnings quality.
• Dependence on Dupixent through the Sanofi partnership, and the eventual biosimilar clock on key products.

As of 2026-08-27, REGN is a high-quality, defensively-positioned biotech with real revenue momentum and a cleaner balance sheet after the Sanofi repayment. But at $807.71, the stock is not cheap enough to be a high-conviction buy: forward earnings are reasonably valued, the litigation overhang exists, and Q2 cash flow was weak. I would treat it as a solid core holding to add to on a pullback toward the 50-day moving average rather than chase at current levels.

Applied a 16.0x multiple to the next-fiscal-year EPS estimate of $54.24, a discount to the 5-year average P/E of 17.0x to reflect litigation and biosimilar risk, but a premium to the current 14.9x forward multiple to reflect the Sanofi repayment and Dupixent/Eylea HD momentum. 16.0 x $54.24 = $868.